dedup-isc-ft-v107-score
float64 0.3
1
| uid
stringlengths 32
32
| text
stringlengths 1
17.9k
| paper_id
stringlengths 8
11
| original_image_filename
stringlengths 7
69
|
|---|---|---|---|---|
0.452819 | 60fc67dc419142cb9d3a0e63f6f3c904 | (A): radial-ebus probe endobronchially; (B): radial-ebus probe ultrasound image; (C): fluoroscopy. (D): patient intubated with double lumen endotracheal tube with inlet for the endoscope and fogarty balloon; (E): ERBE cryoprobe; (F): lung parenchyma tissue sample. | PMC10144839 | medicina-59-00787-g001.jpg |
0.407362 | b8cf3310d8694a1cbac066ac1e54e1a7 | Table of medical history plus age and CT readings distribution. Left: disease distribution, Right: Distribution of age with computed tomography findings. IPF: idiopathic pulmonary fibrosis, LIP: lymphoid interstitial pneumonia, HP: hypersensitivity pneumonia, BIP: bronchiolitis obliterans pneumonia, CTD1: connective tissue disease, DIP: desquamative interstitial pneumonia, COPD: chronic obstructive pulmonary disease, LC: lung cancer, PH: pumonary hypertension, CHD: coronary heart disease, DM: diabetes melitus. | PMC10144839 | medicina-59-00787-g002.jpg |
0.401826 | afe78c2e31b24df1abc5f6434f254745 | Graphical cross-tabulation between old and new diagnoses as affected by change in diagnosis (0.1). Red bars: changes; Blue bars: no changes. | PMC10144839 | medicina-59-00787-g003.jpg |
0.449051 | e09b3efd2a28452ca61ac4c75bf688c8 | Illustration of direct contact membrane distillation. | PMC10144847 | polymers-15-01821-g001.jpg |
0.481858 | 2d1f06e8d83748b688529eb21ec9f985 | Flowchart for numerical optimization model in direct contact membrane distillation. | PMC10144847 | polymers-15-01821-g002.jpg |
0.3774 | b2ad4d7bfa1846b9a32fff5166956b9e | Numerical validation of predicted and theoretical flux with respect to experimental permeate flux for polystyrene membranes in pilot scale DCMD. | PMC10144847 | polymers-15-01821-g003.jpg |
0.505592 | cabc0ff30dc84b0ba7653fb7f7beca36 | Effect of varying membrane porosity with respect to change in the bulk feed temperature and membrane thickness at a Tb,p of (a) 20 °C, (b) 25 °C, and (c) 30 °C. | PMC10144847 | polymers-15-01821-g004.jpg |
0.396108 | 50daa8d1b0d143619135e5c2090a3023 | Effect of bulk temperatures on thermal efficiency in DCMD. | PMC10144847 | polymers-15-01821-g005.jpg |
0.429651 | 69d44a88c4c6435ebed80199100aabdb | Effect of bulk temperatures on evaporation efficiency in DCMD. | PMC10144847 | polymers-15-01821-g006.jpg |
0.41024 | c47fcb9a1bd846aab7a8801e261b0859 | Permeate flux vs. both thermal efficiency and evaporation efficiency of polystyrene membranes at fixed Tb,p = 20 °C and changing Tb,f from 60 °C to 80 °C in (a–c), respectively. | PMC10144847 | polymers-15-01821-g007.jpg |
0.536274 | 9507cfad156842c98aa0e0e3cbf87dfc | Effect of change in membrane porosity on permeate flux in DCMD. | PMC10144847 | polymers-15-01821-g008.jpg |
0.379651 | 8420346dc92848358e7b218798e816eb | Mass transfer coefficient with respect to change in bulk feed and permeate temperature. | PMC10144847 | polymers-15-01821-g009.jpg |
0.425377 | 715ccc8cf896492aaaab403022cf7f7f | BaV chromatographic profile and electrophoretic profiles of F2 fraction and the BaV. (A) Sixty milligrams of lyophilized venom were subjected to a chromatography step on an affinity column, equilibrated, and eluted with 25 mM TRIS, pH 8. Samples were eluted at a continuous flow rate of 1 mL/min, and the protein content was monitored under absorbance at 280 nm on the UPC-900 reader. (B) Five µg of BaV and five µg of the F2 fraction were subjected to gradient gel electrophoresis (5% for the upper gel and 12% for the lower gel) under non-reducing conditions. The bands were revealed by silver nitrate impregnation. | PMC10145261 | toxins-15-00264-g001.jpg |
0.528458 | 91aa69d3be11488e84f8bebfb91e321e | Cross-recognition by ELISA of the venoms of snakes of the genus Bitis against the F2 anti-fraction antibody. Cross-recognition of antibodies against B. arietans, B. gabonica, B. nasicornis and B. rhinoceros venoms was determined by the ELISA method in 96-well plates sensitized with one µg of antigen/well. The anti-F2 fraction antibodies were serially diluted (1:500 to 1:256.000) in PBS/BSA 0.1%. Detection with peroxidase-conjugated “anti-mouse” antibodies was performed at a dilution of 1:5000. The reading was taken with ELX 800 plate spectrophotometer (Biotek Instruments, Vermont, USA) at a wavelength of 490 nm. The yield was presented as ELISA units/mL (EU/mL). The assay was performed in duplicate. Data were statistically analyzed using GraphPad Prism version 7 for Windows (GraphPad Software, San Diego, CA, USA). The yield was presented as units per milliliter. * p < 0.05. | PMC10145261 | toxins-15-00264-g002.jpg |
0.528021 | fd5d11c192084647956b9a107db9caac | Cross-recognition by immunoblotting of venoms from snakes of the genus Bitis against the anti-F2 fraction antibody. (A) Five µg of each venom and five µg of the F2 fraction were subjected to gradient gel electrophoresis (5% for upper gel and 12% for lower gel) under non-reducing conditions. The bands were revealed by silver nitrate impregnation. (B) The nitrocellulose membrane was incubated for 1 h at room temperature with the anti-F2 fraction antibody diluted 1:200 in PBS/BSA 0.1%. After washing with PBS/Tween-20 0.5%, the membrane was incubated for 1 h at room temperature with the “anti-mouse” IgG antibody conjugated with alkaline phosphatase, diluted 1:5000 in PBS/BSA 0.1%. | PMC10145261 | toxins-15-00264-g003.jpg |
0.481398 | bc6569006e3c48eea42fc4b9db0a30ea | Experimental plasma affinity. A 96-well plate was primed with one µg of antigen/well, and the dilution of anti-F2 fraction antibodies was set at 1:1000. KSCN concentration ranged from 0 M to 5 M. The percentage of antibodies bound to 3 M KSCN was used to calculate affinity. (A) F2 affinity curve. (B) raw venom affinity curve. (C) percentage of antibodies bound to KSCN 5M. The assay was performed in duplicate. Data were statistically analyzed using GraphPad Prism version 7 for Windows (GraphPad Software, San Diego, CA, USA). The yield was presented as units per milliliter. | PMC10145261 | toxins-15-00264-g004.jpg |
0.428762 | 0e28c1e3cc7342b69b04c9c3a398f04b | Hemorrhagic activity of BaV. Groups of mice (n = 20) were inoculated by intradermal injection with increasing amounts of BaV or PBS pH 7.2. (A) Hemorrhagic tissue fragments corresponding to 10 µg/animal. (B) Hemorrhagic tissue fragments corresponding to 20 µg/animal. (C) Hemorrhagic tissue fragments corresponding to 30 µg/animal. (D) Fragments of hemorrhagic tissue corresponding to 40 µg/animal. (E) Fragments of hemorrhagic tissue corresponding to PBS pH 7.2 inoculation in control animals. The diameter of the area of each tissue fragment was plotted in the ImageJ 1.8.0 program and expressed in mm2. | PMC10145261 | toxins-15-00264-g005.jpg |
0.413556 | b7d96bc94deb406db58485489a3eec7e | Serum neutralization of BaV hemorrhagic activity. Groups of mice (n = 16) were inoculated by intradermal injection with the MHD of 10 µg of BaV together with different concentrations of the anti-F2 fraction antibody, or PBS pH 7.2. (A) Hemorrhagic tissue fragments corresponding to 10 µg/animal + anti-F2 fraction antibodies 1:5. (B) Hemorrhagic tissue fragments corresponding to 10 µg/animal + antibodies anti-F2 fraction 1:10. (C) Hemorrhagic tissue fragments corresponding to 10 µg/animal + antibodies anti-F2 fraction 1:20. (D) Hemorrhagic tissue fragments corresponding to the inoculation of 10 µg/animal of BaV in PBS pH 7.2 in control animals. The diameter of the area of each tissue fragment was plotted in the ImageJ 1.8.0 program and expressed in mm2. | PMC10145261 | toxins-15-00264-g006.jpg |
0.464048 | 6506d63ce7d242dfbeb8e8727a5efb8a | (a) Flow chart of individuals with ChAdOx1 nCoV-19 vaccination according to pre-existing adenovirus immunity; (b) Timetable of individuals with ChAdOx1 nCoV-19 vaccination. | PMC10145356 | vaccines-11-00784-g001a.jpg |
0.445716 | 9303b3a9f4ef41559d10144a0df0f49a | (a) Spike (S)-specific IgG titers after ChAdOx1 nCoV-19 vaccination according to pre-existing adenovirus immunity; (b) Plaque reduction neutralization test (PRNT50) data after ChAdOx1 nCoV-19 vaccination according to pre-existing adenovirus immunity; *, p < 0.05. | PMC10145356 | vaccines-11-00784-g002a.jpg |
0.441288 | c866b3e4c1e749fe866cbc11cf294e1d | Reactogenicity to ChAdOx1 nCoV-19 vaccination according to pre-existing adenovirus immunity. | PMC10145356 | vaccines-11-00784-g003.jpg |
0.46021 | 2859688cc6cc4251b7ef3e1477e587a7 | Synthesis of compounds (2–22)a–c. | PMC10145568 | microorganisms-11-00935-sch001.jpg |
0.43737 | 113480b204f741ed814a090edf6c8a51 | Normal pregnancy. | PMC10146335 | metabolites-13-00545-g001.jpg |
0.580729 | 44bf4bdfbab8499b83fff2c1ee7fb9a0 | Intrauterine growth restriction. | PMC10146335 | metabolites-13-00545-g002.jpg |
0.466037 | 57a7ab5ec0594f8d8f19a8fc028207e1 | Inherited obesity. | PMC10146335 | metabolites-13-00545-g003.jpg |
0.417491 | 739fc2acff284e309d092989e8290de5 | Dry weight of MS (main stem, (a)), LB (lateral branch, (b)), LMS (leaf on main stem, (c)) and LLB (leaf on lateral branch, (d)) in K. pentacarpos cultivated in non-polluted or polluted soil for five months in the presence or absence of NaCl or/and EDDS. Each value is the mean of 3 replicates and vertical bars are S.E. Values exhibiting different letters are significantly different at p < 0.05 according to SNK test. | PMC10146522 | plants-12-01656-g001.jpg |
0.469985 | c50aacd8b3064dc8ac86cf40265f76c7 | Growth parameters of K. pentacarpos in non-polluted or polluted soil during five months in the presence or absence of NaCl or/and EDDS. The stem height (a), number of lateral branch (LB, (b)), number of leaves on main stem (LMS, (c)), and number of leaves on lateral branch (LLB, (d)) were recorded every two weeks until the 16th week (a–d). Total number of flowers (e) and fruits (f) were recorded every ten days from the first day that they appeared, in total, 9 and 8 times, respectively. Each value is the mean of 15 replicates and vertical bars are S.E. in Figure 1a–d. | PMC10146522 | plants-12-01656-g002.jpg |
0.528773 | 2c448ebdbbe746fbbba973fa0ba93bec | Cardiac Output during labor in the whole population studied | PMC10147743 | 404_2022_6658_Fig1_HTML.jpg |
0.50549 | 53354f1456ce4de8846e480af81acd14 | Cardiac Output during labor in the subgroup with Low Total Vascular Resistances (Low-TVR solid line) and in the subgroup with high Total Vascular Resistances (High-TVR dotted line) | PMC10147743 | 404_2022_6658_Fig2_HTML.jpg |
0.379721 | 646b74b0fb7b498ea246d1b63a2a960f | Number of decelerations at computerized cardiotocography related to Cardiac Output | PMC10147743 | 404_2022_6658_Fig3_HTML.jpg |
0.517519 | c79dec8e9fde4d8392e8ece56b119365 | Short term variation at computerized cardiotocography in the subgroups with low Total Vascular Resistances (Low-TVR) and with high Total Vascular Resistances (High-TVR) | PMC10147743 | 404_2022_6658_Fig4_HTML.jpg |
0.428595 | 87e6d075759e4a5ead875d99b49c7ce5 | Annual climate-related finance commitments, US$ billion (2015–2020). Source: author’s compilation based on OECD DAC’s Creditor Reporting System | PMC10147898 | 11027_2023_10062_Fig1_HTML.jpg |
0.452953 | 960d578d4a6a42b5a059334d425bfd00 | Annual climate-related finance commitments principal versus significant, US$ billion (2015–2020). Source: author’s compilation based on OECD DAC’s Creditor Reporting System | PMC10147898 | 11027_2023_10062_Fig2_HTML.jpg |
0.463654 | 87d30d45b64149d4a65521a321d86204 | Flow chart of the study. | PMC10147972 | gr1.jpg |
0.703568 | 6297630e9bcf4ad2a004f7f7d67b586f | General structure of an acoustic guitar with the detail of its wood components. | PMC10147972 | gr2.jpg |
0.425923 | 863b8e4b6eed49b8858d93dcf3ebf479 | Most commonly employed woods and wood-based composites in acoustic guitars. Only components with a utilization rate greater than 5% are shown. | PMC10147972 | gr3.jpg |
0.384477 | 31d64617b16d40d99a4c62470d5ea431 | Distribution of woods and wood-based composites per guitar component. Only components with a utilization rate greater than 5% are shown. Colors refer to guitar components: light blue = top; orange = brace; grey = back & sides; yellow = bridge; purple = neck; green = fingerboard; dark blue = headplate. | PMC10147972 | gr4.jpg |
0.38842 | c2ad819e84d849d8871aeccf9db27370 | Specific module (E[N/mm2]/⍴[kg/m3]) distribution of woods used for the top (blue) and the back and sides (orange). Only woods with a utilization rate greater than 1% are considered. | PMC10147972 | gr5.jpg |
0.453954 | cd59c6de0fff4d94bcb4eabb262143b4 | Distribution of Janka hardness values [N] of the woods used in the different components. Blue = top; orange = back and sides; grey = bridge; yellow = brace; dark blue = neck; green = fingerboard; purple = headplate. | PMC10147972 | gr6.jpg |
0.442952 | 07454a03ede74a7185b1853c8fd4b3dc | Participant flow diagram. | PMC10148208 | formative_v7i1e44503_fig1.jpg |
0.489708 | 2a51b162d4fc4011bcc4196c6d969f35 | Flow chart of the study design | PMC10149026 | 13063_2023_7309_Fig1_HTML.jpg |
0.471421 | 421f7e8a871a49379755c5f8288e4cdd | Patient with a confirmed monoclonal kappa light chain only disease immunopurified using anti-kappa nanobody beads. The deconvoluted mass spectrum from the CD138 + plasma cell lysate is shown on the top of the figure and the matching deconvoluted mass spectrum from the serum is shown on the bottom. The monoclonal kappa light chain molecular mass observed in the cell lysate and in the serum are listed. An additional peak is observed in the mass spectrum from the serum at a higher molecular mass of 23,599.4 Da which is thought to be a glycated form of the monoclonal kappa light chain having a mass difference between the two peaks is 162 Da which is equivalent to the mass of a hexose. | PMC10149385 | gr1.jpg |
0.4556 | ca88e0aba7d54300858a6f4c138e8883 | Summed mass spectra from outside the retention time window for the monoclonal kappa light chain (4.5 to 9 min). In this retention time window other polyclonal kappa light chains would be expected to elute off the LC column. The mass spectrum from serum shows a Gaussian shaped molecular mass distribution obtained from the polyclonal kappa light chain background originating from normal plasma cells secreting immunoglobulins into circulation that is not observed in the cell lysate sample. | PMC10149385 | gr2.jpg |
0.508458 | faa8918e63db4f6d98b372176e769652 | ESI mass spectra from cell lysates and serum after immunopurification of a patient with an IgA lambda monoclonal immunoglobulin using anti-lambda nanobody beads. Molecular masses for the monoclonal lambda light chain determined after deconvolution are also shown in the figure. | PMC10149385 | gr3.jpg |
0.484562 | 88b2ae0729d54d7ab399e5e21e8d5cb5 | Monoclonal IgA heavy chain ESI mass spectrum (top) displaying the multiply charged monoclonal IgA heavy chains (+30 to + 54 charge states) from the same IgA lambda positive patient shown in Fig. 3. The mass spectrum on the bottom of the figure is the deconvoluted form of the ESI mass spectrum showing different IgA heavy chain glycoforms of the monoclonal heavy chain that differ in molecular mass by 162 Da matching the mass of a hexose monomer. | PMC10149385 | gr4.jpg |
0.429761 | 9ec14d07d7b34176811d78a034d55a9e | Serum derived ESI mass spectrum generated by summing mass spectra in the total ion chromatogram at 10.8 min from the same IgA lambda positive patient shown in Fig. 3. No discernable multiply charged ion envelopes that match those shown in the top of Fig. 4 are observed (top). After deconvolution (bottom) no peaks are observed that match the monoclonal heavy chain glycoforms seen in the cell lysate. | PMC10149385 | gr5.jpg |
0.461419 | 823467c092c44686be8304d3a866439d | Deconvoluted IgG heavy chain mass spectra from a patient with a confirmed IgG kappa monoclonal immunoglobulin after immunopurification using anti-human kappa light chain beads. The mass spectrum on the top is from the cell lysate sample and the mass spectrum on the bottom is from the serum sample. The molecular mass of the primary glycoform is labeled in each mass spectrum. | PMC10149385 | gr6.jpg |
0.503518 | 031d749932254eb8a1801eafbe741421 | Deconvoluted IgG heavy chain mass spectra from a patient with a confirmed IgG lambda monoclonal immunoglobulin after immunopurification using anti-human kappa light chain beads. The mass spectrum on the top is from the cell lysate sample and the mass spectrum on the bottom is from the serum sample. The molecular mass of the primary glycoform is labeled in each mass spectrum. | PMC10149385 | gr7.jpg |
0.426852 | 3e25e5b081f149efa5cee6e499a24401 | (A) Magnetic resonance imaging of patients with different levels of IVDD according to Pfirrmann grades. (B) The results of IHC for human NP tissue sections demonstrated that the expression of Sirt3 was decreased with the progression of degeneration. (C, D) The expression change of Sirt3 in IVDD was further confirmed by western blotting assay, which was accordance with the result of IHC. (E). The IF for mouse intervertebral disc tissue sections proved the down-regulated Sirt3 after IVDD. (F) The expression of Sirt3 was lower in HNP cells treated with TBHP. (G, H) The administration of TBHP for HNP cells made the Sirt3 expression dropped significantly compared with control group. (I) IHC results demonstrated the lower expression of GPX4 and FTH after IVDD. (J–M) The results of qPCR proved that the expression of ACSL4 and PTGS2 was enhanced while GPX4 and FTH was decreased after IVDD. (N, O) The result of WB further confirmed the above results. (P) ELISA proved that the ferric ion increased with the progression of IVDD. ∗ for p < 0:05, ∗∗ for p < 0:01, ∗∗∗for p < 0:001, ∗∗∗∗ for p < 0:0001. | PMC10149406 | gr1.jpg |
0.455381 | ab5a15f22bb54f899a53bae65586f178 | (A) HE staining showed the morphology of mice discs, more severe rupture between the annulus fibrosus and nucleus pulposus was observed in Sirt3−/− group. (B) SF staining proved that KO of Sirt3 was associated with more severe IVDD with internuclear fibrosis. (C) Histological grades were calculated based on HE staining and SF staining results. (D) IHC results revealed that higher expression of ADAMTS5 and MMP3 in Sirt3−/− group after 6 months from the construction of IVDD model was confirmed. (E) The co-immunofluorescence of ACAN and MMP3 for HNP cells indicated that KO of Sirt3 promoted higher expression of ACAN and lower expression of MMP3. (F) Enhanced expression of ADAMTS5 and MMP3 and down-regulated expression of ACAN and Col2 was observed in WB results. (G) Reduced signal intensity was observed in Sirt3−/− group, which proved that KO of Sirt3 leaded to more severe IVDD. (H–K) The qPCR results accorded with the results above. (L–O) Pain-related behavioral scores, including pressure tolerance, distance walked, total active time and maximum speed, were significantly compromised in Sirt3−/− group with increasing IVDD duration. ∗ for p < 0:05, ∗∗ for p < 0:01, ∗∗∗for p < 0:001, ∗∗∗∗ for p < 0:0001, ns for no significance. | PMC10149406 | gr2.jpg |
0.537857 | 832b515c63914a7fb9aa1e9ff6015c98 | (A) Detailed information of the experimental group in the part of the experiment involving oxidative stress. (B, C) KO of Sirt3 could significantly decrease the expression of anti-oxidative stress genes (HO-1, NQO1, SOD2 and SCC7A11). (D) The superoxide was increased with increasing time of TBHP treatment, and higher superoxide was observed in Sirt3-KO group at each time point. (E–H) The above result was further confirmed by qPCR. (I) Mitochondrial superoxide was up-regulated after the treatment of TBHP, which was exacerbated by KO of Sirt3. (J) Detailed information of the experimental group in investigating the effect of KO of Sirt3 on oxidative stress-induced ferroptosis. (K, L) The WB result revealed that the expression of anti-ferroptosis genes (GPX4 and FTH) were decreased while pro-ferroptosis genes (PTGS2 and ACSL4) was increased in NP cells after treated with TBHP, the deletion of Sirt3 exacerbated ferroptosis induced by oxidative stress, which could be reversed by specific oxidative stress inhibitor NAC. (M) As shown in the result of ELISA, the content of MDA and ferric ion was increased significantly in Sirt3−/−, while GSH was dropped. (N, O) Non-peroxidative state shows red fluorescence, while peroxidative state shows green fluorescence in BODIPY assay. The result suggested that the level of lipid peroxidation was the most up-regulated in Sirt3 KO group after exposed to TBHP. (P) Mitochondrial morphology changed the most in Sirt3 KO accompanied with administration of TBHP, which was reversed partly by NAC. (Q–T) The result of qPCR was in accordance with the above results. ∗ for p < 0:05, ∗∗ for p < 0:01, ∗∗∗for p < 0:001, ∗∗∗∗ for p < 0:0001. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.) | PMC10149406 | gr3.jpg |
0.389958 | 00059368840449c1bf791dbda41f7d33 | (A) The result of IP/MS demonstrated that USP11 was identified to be a putative protein binding to Sirt3. To further confirm the result of IP/MS, Co-IP analysis was conducted subsequently. (B) USP11 precipitated Sirt3 in NP cells, confirming the interaction of USP11 and Sirt3. (C) Reverse Co-IP revealed that USP11 was precipitated by Sirt3 in HP cells. The Co-IP analysis using epitope-tagged proteins was further performed. (D, E) the Co-IP test with exogenous Flag-tagged USP11, or Myc-tagged Sirt3 in HEK 293 T cells could precipitate endogenous Sirt3 or USP11, respectively. (F, G) Exogenous Flag-tagged USP11 and Myc-tagged Sirt3 could co-precipitate each other efficiently in HEK 293 T cells. (H) The data above proved the interactions of USP11 and Sirt3, which could be enhanced after IVDD. (I) The schematic diagram showed that USP11 and Sirt3 contains several domains. (J, K) Full length or truncated segments of Flag-USP11 and Myc-Sirt3 containing different domains were transfected in HEK 293 T cells to investigate the binding region. (L) The Co-IP revealed that the fragment containing DUSP domain of USP11 was able to bind Sirt3. (M) Reverse Co-IP proved that USP11 interacted with M2 domain of Sirt3. | PMC10149406 | gr4.jpg |
0.415071 | 026cae0454114db693b0cb35f5203139 | (A) The expression of Sirt3 declined spontaneously with time in the presence of protein synthesis inhibitor cycloheximide (CHX, 10 μg/ml), which could be reversed by proteasome specific inhibitor MG132. Next, siRNA-USP11 or siRNA-Ctrl was transfected into HNP cells and the expression of Sirt3 was analyzed using immunoblotting. (B) The expression of Sirt3 dropped significantly after knockdown of USP11. (C) On the contrary, overexpression of USP11 stabilized the expression of Sirt3. (D) The results above were confirmed again in HEK 293 T cells. (E, F) Overexpression of normal USP11 could upregulate the Sirt3 expression, while overexpression of USP11 with C318S mutant did not. (G) The de-ubiquitination of Sirt3 was abolished effectively by knockdown of USP11. (H) HEK 293 T cells were co-transfected with plasmid of Flag-USP11, Myc-Sirt3 and HA-Ub. The results demonstrated that the deubiquitinate effect of USP11 on Sirt3 was proved. (I) The de-ubiquitination of Sirt3 was abolished in IVD in USP11−/− mice compared with wild mice. (J) Higher de-ubiquitination of Sirt3 and higher expression of Sirt3 was observed after IVDD in mice injected with AAV-USP11. (K) USP11 could cleave the Lys48-polyubiquitin chain instead of Lys63-polyubiquitin chain. (L). Lys48-linked poly-ubiquitination was necessary for de-ubiquitination of Sirt3 regulated by USP11. | PMC10149406 | gr5.jpg |
0.482359 | a4f92985428643bda2a7fe6af89c6867 | (A) Detailed information of the experimental group in the part of the experiment. (B, C) Ferroptosis events were exacerbated by knockdown of Sirt3, including increased expression of ACSL4 and PTGS2, and decreased expression of GPX4 and FTH, which could be ameliorated by overexpression of USP11. (D) ELISA revealed that contents of MDA and ferric ion in supernatant were surged significantly, but GSH dropped with statistical significance in siRNA-Sirt3 group, which could be reversed by co-transfected with plasmid-USP11. (E–H) The results of qPCR for ferroptosis-related genes showed the same trend. (I) After plasmid-USP11 treatment, the morphology of mitochondria maintained well, whereas pretreatment with siRNA-Sirt3resulted in a significant decrease in mitochondrial cristae. (J) The feature of BODIPY assay is that the higher the green fluorescence intensity, the higher the lipid peroxidation level. Thus, as presented, the level of lipid peroxidation was much higher after the treatment of siRNA-Sirt3, which was reversed partly by plasmid-USP11. (K, L) WB proved that siRNA-Sirt3 resulted in enhanced expressions of ADAMTS5 and MMP3 and down-regulated expressions of ACAN and Col2, while plasmid-USP11 could mitigate IVDD. (M − P) The results above were further confirmed using qPCR. ∗ for p < 0:05, ∗∗ for p < 0:01, ∗∗∗for p < 0:001, ∗∗∗∗ for p < 0:0001. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.) | PMC10149406 | gr6.jpg |
0.548147 | a9d91ba001c14f628622e94fc54d5437 | (A) Detailed information of the experimental group in the part of the experiment. (B, C) KO of USP11 resulted in more severe IVDD, indicated by disrupted boundary between NP and AF tissue and decreased NP cells. (D) IHC results revealed that ADAMTS5 and MMP3 were increased significantly after KO of USP11, while AAV-Sirt3 could improve IVDD both in WT and USP11−/− mice. (E) KO of USP11 resulted in increased expression of MMP3 (green fluorescence) and decreased expression of ACAN (red fluorescence), which was reversed partly by AAV-Sirt3. (F, G) WB further confirmed the protective effect of AAV-Sirt3 on IVDD induced by KO of USP11. (H–K) The results above were further confirmed by qPCR. (L–O) KO of USP11 resulting in poor pain-related behavioral scores was proved, which, however, could be improved by AAV-Sirt3. ∗ for p < 0:05, ∗∗ for p < 0:01, ∗∗∗for p < 0:001, ∗∗∗∗ for p < 0:0001. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.) | PMC10149406 | gr7.jpg |
0.413983 | 1b351efab40c4f8d85245d0fa80c8357 | USP11 regulates oxidative stress-induced ferroptosis after IVDD by deubiquitinating Sirt3. Ferroptosis is associated closely with the process of IVDD. The direct interaction of USP11 and Sirt3 is a crucial molecular event that inhibit oxidative stress-induced ferroptosis, thus improves IVDD and relives pain reaction. | PMC10149406 | gr8.jpg |
0.435609 | 4744a6cfbd854441ad1ca2d3b8658eab | Visualization of Hospitals Red and Blue with corresponding time
boundaries and supply. | PMC10149497 | 10.1177_03611981221095745-fig1.jpg |
0.495912 | 15811d60fc4d42b19096ec76e668bc40 | Number of visitors for each hospital during the first halves of 2019 and
2020, organized by visitor demographic. | PMC10149497 | 10.1177_03611981221095745-fig2.jpg |
0.508283 | 777946e8d1c04a989101df7ba8720a88 | Travel times to hospitals within the state of Texas. | PMC10149497 | 10.1177_03611981221095745-fig3.jpg |
0.432935 | 9bcaba4b5fec40e58334ff3996435f06 | Hospital desert index for the state of Texas. | PMC10149497 | 10.1177_03611981221095745-fig4.jpg |
0.394481 | ed540cdd6be74ae7b89ce60129c99597 | Hospital desert index for the cities of Austin, Dallas-Fort Worth, San
Antonio, and Houston. | PMC10149497 | 10.1177_03611981221095745-fig5.jpg |
0.463633 | 36f8e271872f4e8994eeceeb348744cf | Patient selection flow chart. Inclusion criteria included those with complete RHC, PFT and MRI data and exclusion criteria included those with lung diseases not meeting criteria of major lung disease classes or those with coexisting disorders such as left heart disease. The classification of the derivation and test sets was according to the availability of their echocardiography data, where the derivation set of patients had no echocardiography measures. PH: pulmonary hypertension; RHC: right heart catheter; RFT: pulmonary function tests; MRI: magnetic resonance imaging. | PMC10149807 | fcvm-10-1016994-g001.jpg |
0.488048 | 38eb06c1f95142b48143e0f36c013027 | Example cardiac MRI images in patients with mPAP below (left) or above (right) 35 mmHg: PA area (A, B), systolic septal angle (C, D) and VMI (E, F). The patient with severe PH (right) had much larger systolic and diastolic PA areas, systolic septal curvature and VMI than the patient with mild-moderate PH (left). mPAP: mean pulmonary artery pressure; CLD: chronic lung disease; PH: pulmonary hypertension; PA: pulmonary artery; VMI: ventricular mass index; MRI: magnetic resonance imaging. | PMC10149807 | fcvm-10-1016994-g002.jpg |
0.446748 | 100d0cdca7084b32928233493cceea52 | ROC curves for performance of models in severe PH (mPAP ≥ 35 mmHg OR mPAP >25 and CI < 2l/min/m2). ROC: receiver operating characteristic curve; AUC: area under the ROC curve; mPAP: mean pulmonary artery pressure; CI: cardiac index; CLD: chronic lung disease; PH: pulmonary hypertension; MRI: magnetic resonance imaging. | PMC10149807 | fcvm-10-1016994-g003.jpg |
0.403727 | bb42d352dd4c4012b1863ca3c3ef8622 | Kaplan meier of whitfield and lung disease CLD-PH MRI model and the RHC measured mPAP. There is an increased mortality above the selected thresholds of Whitfield model, CLD-PH MRI model and RHC-measured mPAP for both definitions of severe PH according to the ESC/ERS guidelines. mPAP: mean pulmonary artery pressure; PVR: pulmonary vascular resistance; CI: cardiac index; CLD: chronic lung disease; PH: pulmonary hypertension; RHC: right heart catheter; MRI: magnetic resonance imaging. | PMC10149807 | fcvm-10-1016994-g004.jpg |
0.458574 | 9d9bca23f2a440c3aaa50aa44d9db930 | Changes in mean arterial pressure from period A to B. Period A was defined as the average from reversal, and both 2 and 5 min after reversal. Period B was defined as the average from 10 to 15 min after reversal. | PMC10150384 | fneur-14-1045847-g0001.jpg |
0.474709 | 0054b813c5e44d71b0ce537378153558 | Changes in heart rate from period A to B. Period A was defined as the average from reversal, and both 2 and 5 min after reversal. Period B was defined as the average from 10 to 15 min after reversal. | PMC10150384 | fneur-14-1045847-g0002.jpg |
0.419878 | 5d187b0cf89a46a19d630aa63bdc8e67 | Study flow. | PMC10151484 | fpubh-11-1079241-g001.jpg |
0.450748 | 88e5d410c80641979de106c1c7e75c27 | Placement and design of the poster. | PMC10151484 | fpubh-11-1079241-g002.jpg |
0.431099 | c21fd7f30e6448b09b67958ceeedb198 | Geographical distribution of countries represented in the dataset. Each country with at least one patient with PID responding to the survey is colored in red. | PMC10151802 | fimmu-14-1166198-g001.jpg |
0.431126 | 8ec116122f3143348ad0a4bc338f57fb | Type of COVID-19 vaccine per dose used in patients with PID that responded to the survey. | PMC10151802 | fimmu-14-1166198-g002.jpg |
0.525709 | 32f76f0ac8c74c828e4cb98aeea0efe3 | Self-reported reasons for hesitancy to get vaccinated against COVID-19 in patients with PID. | PMC10151802 | fimmu-14-1166198-g003.jpg |
0.426171 | 17141340a96448849fabae13e5c96e77 | Percentages of patients with PID reporting local and systemic adverse events after COVID-19 vaccination. | PMC10151802 | fimmu-14-1166198-g004.jpg |
0.425481 | 44ce167551114a7794e01d5dd1a900b1 | SARS-CoV-2 positivity rate in newly arrived migrants over the period of observation | PMC10152432 | 12992_2023_926_Figa_HTML.jpg |
0.526611 | aa325c1e151b482b945652bca399c487 | Origins of ctDNA and technologies for ctDNA MRD detection. Top panel: ctDNA, released from tumor cells via apoptosis, necrosis, and active secretion, can be extracted from the plasma of patients with cancer. Tumor-associated genetic aberrations can be analyzed in the isolated ctDNA. Bottom panel: Several different technologies for ctDNA MRD analysis in solid tumor patients with definitive therapy.cfDNA, cell-free DNA; ctDNA, circulating tumor DNA; MRD, minimal residual disease; NGS, next-generation sequencing; AS-PCR, allele-specific PCR; ddPCR, droplet digital PCR; BEAMing-PCR, Beads, Emulsions, Amplification, and Magneticsing PCR; Safe-SeqS, Safe-Sequencing; CAPP-Seq, Cancer Personalized Profiling by Deep Sequencing; PhasED-Seq, Phased variant Enrichment and detection Sequencing; WGS, whole-genome sequencing; WES, whole-exome sequencing. | PMC10152452 | or-49-05-08543-g00.jpg |
0.487423 | 94b2171a5b74413d98e31c1344415fe0 | Performances of ctDNA-based MRD approaches in various types of solid tumors. ctDNA, circulating tumor DNA; MRD, minimal residual disease; HNSCC, head and neck squamous cell carcinoma; PDAC, pancreatic ductal adenocarcinoma; CAPP-Seq, Cancer Personalized Profiling by deep Sequencing; TARDIS, targeted digital sequencing; Safe-SeqS, Safe-Sequencing System; cSMART, circulating single-molecule amplification and resequencing technology. | PMC10152452 | or-49-05-08543-g01.jpg |
0.432619 | 0fec28641c93431caf0ea0fb1496566b | Overview of variables and considerations of preanalytical and analytical steps in ctDNA MRD measurements. RT, room temperature; IQC, internal quality control; EQA, external quality assessment. | PMC10152452 | or-49-05-08543-g02.jpg |
0.582986 | da663aaf8e334a1ba4af854861265917 | The illustration of the postural controller feedback loop is studied in this paper.The body’s dynamical system is activated by control input u(t) and affected by disturbances w(t). The sensory system receives the motion dynamic x(t) and transfers it to neuromuscular contorted by noise v(t) and time delay td. The delayed sensory information and a buffer of the control input up to the current time u(t) are used in the neuromuscular by EKF method to estimate delayed states. The optimal controller block refers to all optimal methods explained in this work. The reference angular position xref(t) = 0 is considered zero degrees in an upright stance. | PMC10153747 | pone.0285098.g001.jpg |
0.438707 | c277d3d3aae645ffa8f655175dadef2f | Illustration of two joints dynamical model of the human body in standing position.qa and qh represent the angular position of the ankle and hip joints respectively. COM is the location of the center of the system’s total mass, while m1 and m2 are the mass of the lower body and upper body respectively. Lf is the length of the foot. | PMC10153747 | pone.0285098.g002.jpg |
0.416553 | 0c073b0ca2774d638e4b91736a9e2a3a | Phase portraits comparison of the mentioned methods for the ankle joint.The solid black line indicates the small perturbation and the dashed red line illustrates the higher perturbation. | PMC10153747 | pone.0285098.g003.jpg |
0.466004 | 924161fe3be144a383dfa327170cbbef | Phase portraits comparison of the mentioned methods for the hip joint.The solid black line indicates the small perturbation and the dashed red line illustrates the higher perturbation. | PMC10153747 | pone.0285098.g004.jpg |
0.392569 | 1b0bbed7f13d48acb72059acfd7e01af | Energy consumption at each joint for different methods. | PMC10153747 | pone.0285098.g005.jpg |
0.418233 | 4cb0497f4a0e44f9939e25e61969e9ed | Hip versus ankle joints torque for different methods.The solid black line indicates the small perturbation and the red dashed line indicates the higher perturbation. | PMC10153747 | pone.0285098.g006.jpg |
0.40482 | 81bd5d43c20c408fb9d354cc1a272898 | One step ahead prediction of COP with different methods.The subject body parameters are M = 67 kg, L = 1.68 m. The noise is estimated as white noise with a standard deviation of 0.005. The reaction time of the subject is 0.310 s. | PMC10153747 | pone.0285098.g007.jpg |
0.434909 | cc6ccdc3f4d44ba79e982f40243bd661 | COP validation of measured experimental data of a random subject in the data set with the result of the generated COP of each method for the total time of the prediction.The subject body parameters are M = 67 kg, L = 1.68 m. The noise is estimated as white noise with a standard deviation of 0.005. The reaction time of the subject is 0.310 s. | PMC10153747 | pone.0285098.g008.jpg |
0.375252 | ef3bc9842faa4717a37c2c009ab56ba3 | PSD comparison of measured experimental data of a random subject in the data set and the mentioned methods. | PMC10153747 | pone.0285098.g009.jpg |
0.379264 | ea770c95ed4c4a44aeb1b943ee5c5148 | Evolution of changing controllers gain in IPD controller.The upper plot shows the effect of gain change on the total energy consumption in the joints and the RMSE. The lower plot represents the effect on the joints’ torques and standing strategy. | PMC10153747 | pone.0285098.g010.jpg |
0.479211 | 05342d5421254b0fa80742895a1cec3a | Evolution of changing weights in the optimization of the MPC controller.The upper plot shows the effect of gain change on the total energy consumption in the joints and the RMSE. The lower plot represents the effect on the joints’ torques and standing strategy. | PMC10153747 | pone.0285098.g011.jpg |
0.420275 | 2285f8607e044366ac6f36cea675f020 | Evolution of changing the COP distance error’s weight (α) inCOP-BC controller.The upper plot shows the effect of gain change on the total energy consumption in the joints and the RMSE. The lower plot represents the effect on the joints’ torques and standing strategy. | PMC10153747 | pone.0285098.g012.jpg |
0.436304 | 118f7c86d64647abb9bc49d19d2512df | Testing Common-trend Assumption.The regression coefficients of interaction terms between the lag of benchmark pricing factors and yearly fixed effects are plotted in sub-figures. In the figure, the coefficients before the trade war fluctuates around 0.044, −0.3, −0.004, and 0.293 for M, BR, BM, and MKTR, respectively. As shown, there is no heterogeneous time trend before COVID-19 after controlling for other variables, suggesting that the relationship between benchmark pricing factors and returns is constant before COVID-19. | PMC10155417 | gr1_lrg.jpg |
0.51982 | 59885c7c51ca4011a40fffaaa9c320d5 | Impact Factor and CiteScore of IJO over the years (2011 to 2022) show a rising trend | PMC10155555 | IJO-71-1-g001.jpg |
0.393132 | 6f3dbf805e0240ee9572d21131adb543 | Annual citations for manuscripts published in IJO over the years (2011 to 2022) show a steeply rising trend | PMC10155555 | IJO-71-1-g002.jpg |
0.513237 | 67a295bc198948a8b772da06535a7c23 | SCIMAGO Country Ranking in ophthalmic publications, 2021 | PMC10155555 | IJO-71-1-g003.jpg |
0.473213 | 4d40c724a88a42ad8febfc4f0a7abdd3 | Design of the Punctal plug uploaded on thingiverse.com. The design was made on the 3D designing application FreeCAD (original) | PMC10155558 | IJO-71-297-g001.jpg |
0.386292 | bafffdc487bd4703a01bf50340332d2c | Flowchart depicting the steps involved in the process of 3D printing. (original) | PMC10155558 | IJO-71-297-g002.jpg |
0.462296 | 01aaf47728f8497b97d1b4d9af3022bc | The resultant 3D printed Punctal Plug held by a 26 gauge size needle tip seen under a slit lamp microscope (original) | PMC10155558 | IJO-71-297-g003.jpg |
0.493712 | 5039527986904aab8fecde66da2afa9c | PRISMA Flowchart (32). | PMC10157033 | fcdhc-04-1177030-g001.jpg |
0.429473 | 5eb51dd200c240009898e1e2324ca5b2 | Forest plot of meta-analysis for effect of sSMBG versus control (usual unstructured or no SMBG) on HbA1c (%). Data are mean difference (95% confidence internal). Note. DiGEM (51) includes two treatment arms relative to control referred to as Farmer 2007 T1 and T2. NA, Not applicable. | PMC10157033 | fcdhc-04-1177030-g002.jpg |
0.436778 | 2e4666586159413cbb0f6a8380c5e618 | A basic illustration of the midline approach types. (a) The transvermian approach: a midline incision of the inferior half of the cerebellar vermis and retracting the two halves exposing a tumor in the fourth ventricle. (b) The (unilateral) telovelar approach: lateral retraction of the right cerebellar tonsil and opening the tela choroidea exposing a tumor in the fourth ventricle. | PMC10159312 | SNI-14-124-g001.jpg |
0.437209 | c29ee9ac35a04e4183f8759640610a57 | Forest plots showing no significant risk between utilizing the telovelar over the transvermian for (a) postoperative cranial nerve defects, (b) gait/focal motor defects, (c) postoperative speech/ swallowing defects, or (d) postoperative hydrocephalus following fourth ventricle tumor resection. CN: Cranial nerve, FM: Focal motor, S/S: Speech/swallowing, CI: Confidence interval, M-H: Mantel-haenszel, P: P-value, df: degrees of freedom, Z: Cohen’s D effect size. | PMC10159312 | SNI-14-124-g002.jpg |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.